Tumour-associated macrophages in diffuse large B-cell lymphoma: A study of the Osaka Lymphoma Study Group

Histopathology

Volumn 60, Issue 2, 2012, Pages 313-319

  Wada, Naoki ^a   Zaki, Mona A A ^a   Hori, Yumiko ^a   Hashimoto, Koji ^b   Tsukaguchi, Machiko ^c   Tatsumi, Yoichi ^d   Ishikawa, Jun ^e   Tominaga, Nobuhiko ^f   Sakoda, Hiroto ^g   Take, Hironori ^h   Tsudo, Mitsuru ⁱ   Kuwayama, Maki ^j   Morii, Eiichi ^a   Aozasa, Katsuyuki ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KANSAI ROSAI HOSPITAL   (Japan)

^c SAKAI MUNICIPAL HOSPITAL   (Japan)

^d KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^f Suita Municipal Hospital   (Japan)

^g SUMITOMO HOSPITAL   (Japan)

^h TOYONAKA MUNICIPAL HOSPITAL   (Japan)

ⁱ OSAKA RED CROSS HOSPITAL   (Japan)

^j Yao Municipal Hospital   (Japan)

more..

Author keywords

Diffuse large B cell lymphoma; M1 type; M2 type; Prognosis; Tumour associated macrophage

Indexed keywords

CD163 ANTIGEN; CD68 ANTIGEN; HLA DR ANTIGEN; LACTATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; TUMOR ASSOCIATED LEUKOCYTE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; FEMALE; HUMANS; JAPAN; LYMPHOMA, LARGE B-CELL, DIFFUSE; MACROPHAGES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84255178280     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.04096.x     Document Type: Article

References (20)

1. Stein H, Warnke RA, Chan WC et al. Diffuse large B-cell lymphoma, not otherwise specified. In Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW eds. World Health Organization classification of tumours of haematopoietic and lymphoid tissues, 4th edn. Lyon: IARC Press, 2008; 233-237.
2. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403; 503-511.
3. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103; 275-282.
4. Lenz G, Wright G, Dave SS et al. Stromal gene signatures in large-B-cell lymphomas. Lymphoma/Leukemia Molecular Profiling Project. N. Engl. J. Med. 2008; 359; 2313-2323.
5. Farinha P, Masoudi H, Skinnider BF et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005; 106; 2169-2174.
6. Steidl C, Lee T, Shah SP et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N. Engl. J. Med. 2010; 362; 875-885.
7. Wada N, Ikeda J, Kohara M et al. Diffuse large B-cell lymphoma with a high number of epithelioid histiocytes (lymphoepithelioid B-cell lymphoma): a study of Osaka Lymphoma Study Group. Virchows Arch. 2009; 455; 285-293.
8. Hasselblom S, Hansson U, Sigurdardottir M, Nilsson-Ehle H, Ridell B, Andersson PO. Expression of CD68+ tumor-associated macrophages in patients with diffuse large B-cell lymphoma and its relation to prognosis. Pathol. Int. 2008; 58; 529-532.
9. Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L. The origin and function of tumor-associated macrophages. Immunol. Today 1992; 13; 265-270.
10. Mantovani A, Sica A, Locati M. New vistas on macrophage differentiation and activation. Eur. J. Immunol. 2007; 37; 14-16.
11. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N. Engl. J. Med. 1993; 329; 987-994.
12. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J. Clin. Oncol. 1999; 17; 1244-1253.
13. Ma J, Liu L, Che G, Yu N, Dai F, You Z. The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer 2010; 10; 112. Available at.
14. Bronkhorst IH, Ly LV, Jordanova ES et al. Detection of M2 macrophages in uveal melanoma and relation with survival. Invest. Ophthalmol. Vis. Sci. 2011; 52; 643-650.
15. Hasita H, Komohara Y, Okabe H et al. Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma. Cancer Sci. 2010; 101; 1913-1919.
16. Kurahara H, Shinchi H, Mataki Y et al. Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J. Surg. Res. 2011; 167; e211-e219.
17. Fujiwara Y, Komohara Y, Ikeda T, Takeya M. Corosolic acid inhibits glioblastoma cell proliferation by suppressing the activation of signal transducer and activator of transcription-3 and nuclear factor-kappa B in tumor cells and tumor-associated macrophages. Cancer Sci. 2011; 102; 206-211.
18. Komohara Y, Ohnishi K, Kuratsu J, Takeya M. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J. Pathol. 2008; 216; 15-24.
19. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 2008; 8; 958-969.
20. De Wolf-Peeters C, Delabie J, Campo E, Jaffe ES, Delsol G. T cell/histiocyte-rich large B-cell lymphoma. In Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW eds. World Health Organization classification of tumours of haematopoietic and lymphoid tissues, 4th edn. Lyon: IARC Press, 2008; 238-239.